Rite Aid Brand Check-up: Two Bankruptcies in Under Two Years
Rite Aid filed for Chapter 11 for the second time on May 5, 2025, less than two years after its first filing. On May 21 a judge approved the sale of most of its pharmacy assets to rivals. We look at how a chain that ran more than 4,600 stores in 2015 reached this point, and what its brand was missing.
Key takeaways
- Rite Aid’s revenue stayed near $24 billion for three years, but it lost $719.2 million in fiscal 2023 and listed $8.6 billion of debts when it first filed for Chapter 11 in October 2023.
- As a distant third to CVS and Walgreens, it gave shoppers no clear reason to choose it, and its plans to sell to Walgreens and to merge with Albertsons both fell short.
- Opioid claims and a five-year FTC ban on facial recognition put at risk the trust a pharmacy brand depends on.
- After emerging as a smaller private company in September 2024, it filed again on May 5, 2025, and a judge approved the sale of most of its pharmacy assets on May 21.
Download the full Rite Aid Brand Check-up (PDF): vital signs, timeline, diagnosis, treatment and sources.
The symptoms
Rite Aid reported revenue of $24.09 billion for fiscal 2023, the year to March 4, 2023, down from $24.57 billion a year earlier. Its net loss, as revised in an amended filing in July 2024, was $719.2 million. When it filed for Chapter 11 on October 15, 2023, it listed $8.6 billion of debts against $7.6 billion of assets. The shares, which had a record close of $1,019 in January 1999 according to CompaniesMarketCap (adjusted for a 2019 reverse split), closed at about 65 cents on the last trading day before the filing. The New York Stock Exchange suspended trading on October 16. The stock moved over the counter and was cancelled when the company emerged as a private business on September 3, 2024.
A third choice in a two-brand market
Rite Aid ran more than 2,000 stores when it first filed, while CVS and Walgreens each operated several thousand more and had moved into health care, including clinics. Online competitors such as Amazon hurt sales of consumer goods. Pharmacy made up 71.2 per cent of Rite Aid’s drugstore sales in fiscal 2023, so the chain lived on prescriptions, and the Associated Press reported in 2025 that prescription profitability had grown tight. In our view, Rite Aid never settled its brand positioning. Shoppers knew the name, but had no specific reason to pick it over a bigger chain nearby.
Its escape plans relied on others. In October 2015 Walgreens agreed to buy Rite Aid for $9 a share, a 48 per cent premium, then scaled back to buying about 1,900 stores to get past antitrust regulators. A 2018 merger with Albertsons was called off. A plain competitor analysis asks what a smaller rival offers that the leaders do not. For Rite Aid, the record gives no clear answer.
Trust is the product in a pharmacy
In March 2023 the U.S. Justice Department joined a whistleblower lawsuit. Federal officials said the chain filled “at least hundreds of thousands” of illegal prescriptions, including for opioids. Rite Aid called the claims “hyperbolic.” In December 2023 it agreed to a five-year ban on facial recognition. The Federal Trade Commission said false matches had led staff to accuse customers, some of whom were detained and searched, and that the system was mostly deployed in neighbourhoods with large Black, Latino and Asian communities. “Rite Aid’s reckless use of facial surveillance systems left its customers facing humiliation and other harms,” said Samuel Levine, director of the FTC’s Bureau of Consumer Protection. Rite Aid said: “we fundamentally disagree with the facial recognition allegations in the agency’s complaint.” For a pharmacy, these are not side issues. Customers hand over their health details and expect fair treatment at the counter.
A smaller chain, the same problem
Rite Aid emerged from its first bankruptcy owned by its creditors, with about $2.0 billion of debt eliminated. It had shrunk to 1,245 stores in 15 states. Eight months later, on May 5, 2025, it filed again, with $1.94 billion of new financing and a plan to sell substantially all of its assets. The Associated Press described empty shelves at a Philadelphia-area store a few miles from corporate headquarters. “They’re actively pushing customers away,” said GlobalData’s Neil Saunders.
On May 21 a judge approved the sale of most pharmacy assets and the closing of stores. CVS agreed to take over 64 stores in Idaho, Oregon and Washington and the prescription files of 625 more Rite Aid pharmacies. According to Reuters, Rite Aid found buyers for customer files at 810 stores and none for 200 others.
What growing companies can learn
Rite Aid’s name was known across the country, but awareness is not a reason to buy. A brand in third place needs to own a specific moment of need, the kind of category entry point that brings a customer to it first. Trust has to be managed as part of the product, above all where health or money is involved. Cutting stores and debt buys time, but it does not give customers a reason to come back. Fix the reason first.
This check-up uses public information available on June 3, 2025. It is brand and marketing analysis, not investment advice.
Find out where your marketing is bleeding.
Brand Doctor is based in Vancouver and offers a free marketing diagnosis to businesses across Canada, in person or remotely. You leave knowing what’s holding growth back and what to fix first.
